LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license ...

Both patients with IPF and patients with PPF treated with nerandomilast demonstrated a smaller decline in forced vital ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...